Dans le cadre de la réforme du financement des établissements de santé, prévue par la LFSS 2024, l’Igas propose la mise en place d’un financement des actions de prévention primaire. Pour rappel, cette réforme prévoit la création d’un compartiment de dotations relatives aux objectifs de santé publique. C’est dans ce cadre qu’intervient le rapport de […]

The minimal and optimal daily step counts for health improvements remain unclear.A meta-analysis was performed to quantify dose-response associations …

Background: The literature on whether physical activity (PA) and PA and diet (PA+Diet) mobile apps improve cardiovascular disease (CVD) risk factors is promising.
Objective: The aim of this meta-review is to provide an evidence synthesis of systematic reviews and meta-analyses examining the influence of PA and PA+Diet apps on the major CVD risk factors.
Methods: We systematically searched 5 databases until January 12, 2022. Included systematic reviews and meta-analyses (1) reported the CVD risk factor outcomes of BMI, waist circumference, body weight, blood pressure (BP), hemoglobin A1c (HbA1c), fasting blood glucose, blood lipids, or PA; (2) enrolled healthy participants ≥18 years who may or may not have the metabolic syndrome, diabetes mellitus, or preexisting CVD risk factors; (3) reviewed PA or PA+Diet app interventions integrating behavioral change techniques (BCT) to deliver their information; and (4) had a nonapp control.
Results: In total, 17 reviews (9 systematic reviews and 8 meta-analyses) published between 2012 and 2021 qualified. Participants were middle-aged, mostly women ranging in number from 10 to 62,219. Interventions lasted from 1 to 24 months, with the most common behavioral strategies being personalized feedback (n=8), self-monitoring (n=7), and goal setting (n=5). Of the PA app systematic reviews (N=4), the following CVD risk factors improved: body weight and BMI (n=2, 50%), BP (n=1, 25%), HbA1c (n=1, 25%), and blood lipids (n=1, 25%) decreased, while PA (n=4, 100%) increased. Of the PA+Diet app systematic reviews (N=5), the following CVD risk factors improved: body weight and BMI (n=3, 60%), BP (n=1, 20%), and HbA1c (n=3, 60%) decreased, while PA (n=3, 60%) increased. Of the PA app meta-analyses (N=1), the following CVD risk factors improved: body weight decreased (–0.73 kg, 95% CI –1.45 to –0.01; P=.05) and PA increased by 25 minutes/week (95% CI 0.58-1.68; P<.001), while BMI (–0.09 kg/m2, 95% CI –0.29 to 0.10; P=.35) and waist circumference (–1.92 cm, 95% CI –3.94 to 0.09; P=.06) tended to decrease. Of the PA+Diet app meta-analyses (n=4), the following CVD risk factors improved: body weight (n=4, 100%; from –1.79 kg 95% CI –3.17 to –0.41; P=.01 to –2.80 kg 95% CI –4.54 to –1.06, P=.002), BMI (n=1, 25%; –0.64 kg/m2, 95% CI –1.09 to –0.18; P=.01), waist circumference (n=1, 25%; –2.46 cm, 95% CI –4.56 to –0.36; P=.02), systolic/diastolic BP (n=1, 25%; –4.22/–2.87 mm Hg, 95% CI –6.54 to –1.91/ –4.44 to –1.29; P<.01), and HbA1c (n=1, 25%; –0.43%, 95% CI –0.68 to –0.19; P<.001) decreased.
Conclusions: PA and PA+Diet apps appear to be most consistent in improving PA and anthropometric measures with favorable but less consistent effects on other CVD risk factors. Future studies are needed that directly compare and better quantify the effects of PA and PA+Diet apps on CVD risk factors.
Trial Registration: PROSPERO CRD42023392359; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=392359

Convaincus que le « tout numérique » ne doit pas être une fin en soi, mais un outil au service d’un projet ambitieux visant à favoriser les évolutions nécessaires de notre système de santé, le CRAPS et Health & Tech ont réuni une quarantaine d’acteurs pour anticiper la bascule vers une médecine personnalisée, préventive, prédictive, participative.

Si elle n’est pas traitée, la fibrillation auriculaire peut entraîner un accident vasculaire cérébral. Or, un récent sondage met en garde quant au fait que les Français ont une mauvaise connaissance de cette pathologie, en particulier en tant que facteur de risqu

Individuals with autoimmune inflammatory diseases, such as systemic lupus erythematosus,
rheumatoid arthritis, and psoriasis, are at increased risk for cardiovascular disease.
While these diseases share common features of systemic inflammation, the impact of
individual autoimmune inflammatory conditions on circulating lipids and lipoproteins
varies by specific disease, disease activity, and the immune-suppressing medications
used to treat these conditions. A common feature observed in many autoimmune inflammatory
diseases is the development of a proatherogenic dyslipidemic state, characterized
by dysfunctional HDLs (high-density lipoproteins) and increased oxidation of LDLs
(low-density lipoproteins). Various disease-modifying antirheumatic drugs also have
complex and variable effects on lipids, and it is critical to take this into consideration
when evaluating lipid-related risk in individuals with immune-mediated inflammatory
conditions. This review aims to critically evaluate the current understanding of the
relationship between immune-mediated inflammatory diseases and dyslipidemia, the underlying
mechanisms contributing to atherogenesis, and the impact of various pharmacotherapies
on lipid profiles and cardiovascular risk. We also discuss the role of lipid-lowering
therapies, particularly statins, in managing residual risk in this high-risk population
and explore the potential of emerging therapies with complementary anti-inflammatory
and lipid-lowering effects.

Guidelines often recommend that clinicians advise patients on behavior change. In this commentary, authors caution and describe ways that guideline panels may overestimate the evidence that suc

Une découverte alarmante secoue le monde médical : plus de la moitié des plaques d'artères obstruées contiennent des microplastiques. Cette révélation soulève des questions cruciales su